**Supplementary Table 1. Overview of Data Collection from Medical Records in the Gastric/GEJ Cancer EAMS**

|   | **Data Collection in Chart Review** |
| --- | --- |
| At enrolment (baseline) | * Demographics

Age (years), gender, race, prior and pre-existing comorbidities, concomitant medications* Disease characteristics

Primary tumour location, tumour histology (adenocarcinoma), sites of metastases, ECOG performance status* Medical history

Number of prior systemic treatments for advanced gastric or GEJ cancer, prior surgery for gastric or GEJ cancer |
| At treatment discontinuation  | Date of first and last nivolumab treatment administration, clinical disease progression status and date of progression (for patients who progressed), patient survival status, as well as date and primary cause of death (in patients who died) |
| Up to 12 months post-treatment discontinuation | If at the time of discontinuation, progression had not been indicated or the patient had not died, the following outcomes were collected: * Clinical disease progression status and date or progression (for patients who progressed). Only first occurrence of progression was collected. Further progression patterns after initial occurrence of progression (regardless of timing post-nivolumab discontinuation) were not collected.
* Patient survival status, as well as date and primary cause of death (in patients who died).
 |

Abbreviations: ECOG = Eastern Cooperative Oncology Group; GEJ = gastroesophageal junction

**Supplementary Table 2. Disease Characteristics and Medical History at Baseline for Patients Enrolled in EAMS Who Consented to Observational Research**

|  | **Patients Enrolled in EAMS** **Who Consented to** **Observational Research** **(N=113)** |
| --- | --- |
| **Number of prior or pre-existing comorbidities at therapy initiation, n (%)** | **N=110** |
| 0 | 48 (43.6) |
| 1 | 31 (28.2) |
| 2 | 12 (10.9) |
| 3 or more | 19 (17.3) |
| **Most common prior or pre-existing comorbidities at therapy initiationa, n (%)** | **N=110** |
| Hypertension | 20 (18.2) |
| ‘Other’ cardiovascular | 14 (12.7) |
| VTE/pulmonary embolism | 12 (10.9) |
| **Concomitant medications, n (%)** | **N=110** |
| Yes | 96 (87.3) |
| No | 14 (12.7) |
| **Most common types of concomitant medicationsa, n (%)** | **N=110** |
| Proton pump inhibitors | 69 (62.7) |
| Opioid analgesics | 35 (31.8) |
| Antiemetic drugs | 23 (20.9) |
| Antithrombotic drugs | 22 (20.0) |
| Non-opioid analgesics | 21 (19.1) |
| Lipid monitoring agents | 15 (13.6) |
| Agents acting on the renin-angiotensin system | 14 (12.7) |
| Beta blocking agents | 13 (11.8) |
| Vitamins minerals and food supplements | 11 (10.0) |
| **Tumour histology (adenocarcinoma), n (%)** | **N=113** |
| Yes | 112 (99.1) |
| No | 1 (0.9) |

a ‘Most common’ reported comorbidities and concomitant medications are those that were reported in at least 10% of patients who consented to observational research. More than one comorbidity or concomitant medication may have been reported per patient.

Abbreviations: EAMS = Early Access to Medicines Scheme; VTE = venous thromboembolism

**Supplementary Table 3. Demographics, Disease Characteristics, and Medical History at Baseline for Patients Enrolled in EAMS Who Consented to EQ-5D-3L Completion and Returned a Questionnaire**

|  | **Patients Enrolled in EAMS who Consented to EQ-5D-3L Completion and Returned a Questionnaire** **(N=71)a** |
| --- | --- |
| **Age at baseline, years** | **N=71** |
| Median | 63 |
| Range | 32–87 |
| **Gender, n (%)** | **N=71** |
| Male | 55 (77.5) |
| Female | 16 (22.5) |
| **Race, n (%)** | **N=70** |
| White | 66 (94.3) |
| Asian (Indian, Pakistani, Bangladeshi) | 1 (1.4) |
| Asian (Chinese, Japanese, Korean, Taiwanese) | 1 (1.4) |
| Other | 2 (2.9) |
| **Number of prior or pre-existing comorbidities at therapy initiation, n (%)** | **N=70** |
| 0 | 31 (44.3) |
| 1 | 21 (30.0) |
| 2 | 8 (11.4) |
| 3 or more | 10 (14.3) |
| **Most common prior or pre-existing comorbidities at therapy initiationb, n (%)** | **N=70** |
| Hypertension | 11 (15.7) |
| ‘Other’ cardiovascular | 9 (12.9) |
| **Concomitant medications, n (%)** | **N=70** |
| Yes | 60 (85.7) |
| No | 10 (14.3) |
| **Most common types of concomitant medicationsb, n (%)** | **N=70** |
| Proton pump inhibitors | 45 (64.3) |
| Opioid analgesics | 21 (30.0) |
| Antiemetic drugs | 13 (18.6) |
| Non-opioid analgesics | 15 (21.4) |
| Antithrombotic drugs | 10 (14.3) |
| **Primary tumour location, n (%)** | **N-71** |
| Gastric adenocarcinoma | 25 (35.2) |
| Gastroesophageal junction | 46 (64.8) |
| **Tumour histology (adenocarcinoma), n (%)** | **N=71** |
| Yes | 71 (100.0) |
| **Number of organs with metastases, n (%)** | **N=71** |
| ≤1 | 29 (40.8) |
| ≥2 | 42 (59.2) |
| **Sites of metastasesc, n (%)** | **N=70** |
| Lymph node | 49 (70.0) |
| Liver | 26 (37.1) |
| Lung | 17 (24.3) |
| Peritoneum | 18 (25.7) |
| Bone | 7 (10.0) |
| Other | 6 (8.6) |
| **ECOG performance status, n (%)** | **N=71** |
| 0 | 13 (18.3) |
| 1 | 54 (76.1) |
| 2 | 4 (5.6) |
| **Number of prior systemic treatments for advanced gastric or GEJ cancer, n (%)** | **N=69** |
| 2 | 61 (88.4) |
| 3 | 8 (11.6) |
| **Prior surgery for gastric or GEJ cancer, n (%)** | **N=69** |
| Yes | 22 (31.9) |
| No | 47 (68.1) |

a For one patient, the identification number was missing, and the EQ-5D questionnaire data could not be matched with the baseline data

b ‘Most common’ reported comorbidities and concomitant medications are those that were reported in at least 10% of patients who consented to observational research. More than one comorbidity or concomitant medication may have been reported per patient

c More than one site may have been reported per patient.

Abbreviations: EAMS = Early Access to Medicines Scheme; ECOG = Eastern Cooperative Oncology Group; EQ-5D-3L = EuroQoL Five Dimensions, Three Levels questionnaire; GEJ = gastroesophageal junction

**Supplementary Table 4. Descriptive Summary of EQ-5D-3L at Baseline**

|  | **Patients Enrolled in EAMS Who Consented to EQ-5D-3L Completion and Returned a Baseline Questionnaire (N=72)** |
| --- | --- |
| **Mobility, n (%)** | **N=72** |
| No problems walking about | 50 (69.4) |
| Some problems walking about | 22 (30.6) |
| Confined to bed | 0 (0.0) |
| **Self-care, n (%)** | **N=72** |
| No problems with self-care | 66 (91.7) |
| Some problems washing or dressing self | 6 (8.3) |
| Unable to wash or dress self | 0 (0.0) |
| **Usual activities, n (%)** | **N=72** |
| No problems performing usual activities | 43 (59.7) |
| Some problems performing usual activities | 28 (38.9) |
| Unable to perform usual activities | 1 (1.4) |
| **Pain or discomfort, n (%)** | **N=72** |
| No pain or discomfort | 34 (47.2) |
| Moderate pain or discomfort | 37 (51.4) |
| Extreme pain or discomfort | 1 (1.4) |
| **Anxiety or depression, n (%)** | **N=72** |
| Not anxious or depressed | 51 (70.8) |
| Moderately anxious or depressed | 20 (27.8) |
| Extremely anxious or depressed | 1 (1.4) |
| **EQ-VAS score** | **N=69** |
| Mean (SD) | 72.9 (16.2) |
| **Health utility score** | **N=72** |
| Mean (SD) | 0.794 (0.177) |

Abbreviations: EAMS = Early Access to Medicines Scheme; EQ-5D-3L = EuroQoL Five Dimensions, Three Levels questionnaire; EQ-VAS = EuroQoL visual analogue scale; SD = standard deviation